Ac. Liu et al., Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells, HEMATOL ONC, 17(4), 1999, pp. 149-160
In order to develop an effective immunotherapy for hematological malignanci
es, we investigated the applicability of class II transactivator (CIITA), w
hich had been demonstrated to regulate the expression of MHC class IT (MHC-
II) by assembling the transcription factors of MHC-II molecules, for immuno
therapy by potentiating the antigenicity of tumour cells by inducing MHC ex
pression. First, 32 hematopoietic cell lines were analysed for the expressi
on of HLA-DR, CIITA, RFX5 or HLA-ABC. Fourteen cell lines were positive and
18 were negative for HLA-DR. AU the 14 HLA-DR positive cell lines were dem
onstrated to express CIITA mRNA by RT-PCR. On the other hand, in all the 18
HLA-DR negative cell lines, the expression of CIITA was not demonstrated.
RFX5, which is one of the transcription factors of MHC-IT, was expressed ub
iquitously in all 32 cell lines. Three cell lines out of 23 hematopoietic c
ell lines examined were negative for HLA-ABC, and all three of these cell l
ines were negative for both HLA-DR and CIITA expression. Furthermore, CIITA
cDNA was transfected into K562 cells, which were negative for HLA-ABC, -DR
and -DQ, but positive for HLA-DP. The transfection rendered HLA-DR negativ
e to positive and increased the expression level of HLA-DP, but HLA-DQ rema
ined negative. In addition to HLA-DR, HLA-ABC was also induced to express b
y the transfection of CIITA gene. The present study demonstrated that the e
xpression of HLA-DR in hematopoietic cells is regulated in subordination to
CIITA and the expression of HLA-DR (and HLA-ABC in K562) is induced by tra
nsfection with the CIITA gene. These findings revealed the applicability of
CIITA in potentiating antitumour immunity of HLA-DR negative tumour cells
for immunotherapy of hematological malignancies. Copyright (C) 1999 John Wi
ley & Sons, Ltd.